赞比亚婴儿中两种单价轮状病毒疫苗的免疫原性与安全性
在赞比亚6至8周龄婴儿中开展的2b期开放标签随机对照试验显示,ROTAVAC与ROTAVAC 5D均耐受良好且具免疫原性;ROTAVAC 5D在血清IgA几何平均浓度上非劣于ROTAVAC,且未报告死亡或肠套叠病例。
要点
- ROTAVAC 5D在IgA GMC上非劣于ROTAVAC,比值1.3(95%CI 0.9,1.9)。
- 两种疫苗的征集性和非征集性不良事件在各组间相似。
- 研究期间未报告死亡或肠套叠病例。
核心结论
- 在赞比亚婴儿中,ROTAVAC和ROTAVAC 5D均耐受良好,且ROTAVAC 5D的免疫原性非劣于ROTAVAC。
研究设计与样本
- 2b期、开放标签、随机对照试验,450名6至8周龄婴儿等额随机接受三剂ROTAVAC、三剂ROTAVAC 5D或两剂ROTARIX,符合方案人群388名。
主要发现
- 接种后ROTAVAC组和ROTAVAC 5D组的血清IgA(WC3)GMC分别为14.0 U/mL(95%CI 10.4,18.8)和18.1 U/mL(95%CI 13.7,24.0)。
- 两组GMC比值为1.3(95%CI 0.9,1.9),满足预设非劣效标准。
- 征集性和非征集性不良事件在所有研究组间相似。
- 研究期间未报告死亡或肠套叠病例。
关键数值与推荐
- 主要分析为评估ROTAVAC 5D相对ROTAVAC在血清IgA(WC3)抗体GMC上的非劣效性。
- 非劣效性标准为GMC比值95%CI下限不低于预设值,原文未报告具体预设界值。
临床怎么用
- ROTAVAC 5D可在2-8°C储存,便于在资源有限地区推广使用。
- 两种疫苗均可与常规免疫规划同时接种。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: ROTAVAC® (frozen formulation stored at -20 °C) and ROTAVAC 5D® (liquid formulation stable at 2-8 °C) are rotavirus vaccines derived from the 116E human neonatal rotavirus strain, developed and licensed in India. This study evaluated and compared the safety and immunogenicity of these vaccines in an infant population in Zambia. METHODS: We conducted a phase 2b, open-label, randomized, controlled trial wherein 450 infants 6 to 8 weeks of age were randomized equally to receive three doses of ROTAVAC or ROTAVAC 5D, or two doses of ROTARIX®. Study vaccines were administered concomitantly with routine immunizations. Blood samples were collected pre-vaccination and 28 days after the last dose. Serum anti-rotavirus IgA antibodies were measured by ELISA, with WC3 and 89-12 rotavirus strains as viral lysates in the assays. The primary analysis was to assess non-inferiority of ROTAVAC 5D to ROTAVAC in terms of the geometric mean concentration (GMC) of serum IgA (WC3) antibodies. Seroresponse and seropositivity were also determined. Safety was evaluated as occurrence of immediate, solicited, unsolicited, and serious adverse events after each dose. RESULTS: The study evaluated 388 infants in the per-protocol population. All three vaccines were well tolerated and immunogenic. The post-vaccination GMCs were 14.0 U/mL (95% CI: 10.4, 18.8) and 18.1 U/mL (95% CI: 13.7, 24.0) for the ROTAVAC and ROTAVAC 5D groups, respectively, yielding a ratio of 1.3 (95% CI: 0.9, 1.9), thus meeting the pre-set non-inferiority criteria. Solicited and unsolicited adverse events were similar across all study arms. No death or intussusception case was reported during study period. CONCLUSIONS: Among Zambian infants, both ROTAVAC and ROTAVAC 5D were well tolerated and the immunogenicity of ROTAVAC 5D was non-inferior to that of ROTAVAC. These results are consistent with those observed in licensure trials in India and support use of these vaccines across wider geographical areas.
引用
- Chilengi R, Mwila-Kazimbaya K, Chirwa M, et al. Immunogenicity and safety of two monovalent rotavirus vaccines, ROTAVAC® and ROTAVAC 5D® in Zambian infants. Vaccine. 2021. PMID: 33992437. doi:10.1016/j.vaccine.2021.04.060
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。